Eli Lilly's New Compliance Chief on His Priorities

Technological innovation, the coronavirus pandemic and a shifting regulatory landscape are among the topics that are top of mind for pharmaceutical company Eli Lilly & Co.’s new compliance chief, Alonzo Weems. Mr. Weems succeeded Melissa Stapleton Barnes, who retired from the Indianapolis-based

Lilly Covid-19 Antibody Shipments Paused on Variant Concerns

U.S. health officials have paused the distribution of two Eli Lilly LLY -1.18% & Co. Covid-19 monoclonal antibody treatments because of data showing that they aren’t effective against virus variants that are becoming increasingly common across the country. The Department of Health

Eli Lilly to Seek FDA Approval for Alzheimer's Drug

Eli Lilly & Co. plans to seek approval for its Alzheimer’s drug later this year, a sign that regulators are accelerating the prospects of treatments for the disease after a recent approval. Lilly said Thursday that the U.S. Food and Drug Administration

U.S. to Invest More Than $3 Billion in Covid-19 Antiviral Development

WASHINGTON—The Biden administration will invest more than $3 billion on developing and manufacturing antiviral pills to treat coronavirus, the Department of Health and Human Services said Thursday. “New antivirals that prevent serious Covid-19 illness and death, especially oral drugs that could be